Skip to main content
SpringerLink
Log in

Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors

  • Chapter
  • First Online:
Resistance to Immunotherapeutic Antibodies in Cancer

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics ((RTACT,volume 2))

Abstract

The introduction of monoclonal antibodies against checkpoint inhibitors on T cells such as Ipilimumab and anti PD1 has been a major advance in the treatment of metastatic melanoma. Nevertheless, the majority of patients does not receive benefit from this treatment approach. The reasons for this are likely to reflect conditioning of the microenvironment of the tumour by properties of the tumour cells that either prevent infiltration by T cells or which modulate their function. Treatments that combine monoclonal antibodies with agents that inhibit melanoma cell production of suppressive cytokines and which favor infiltration of T cells into the tumour are the focus of ongoing studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

BTLA:

B and T cell attenuator

CT:

Cancer testis

CTLA4:

Cytotoxic lymphocyte antigen 4

EOMES:

Eomesodermin

ICOS:

Inducible costimulator

IDO:

Indolamine dioxygenase

MAbs:

Monoclonal antibodies

NBD:

Nemo binding domain

PD1:

Programmed death receptor 1

TILs:

Tumour infiltrating lymphocytes

Tim3:

T cell immunoglobulin mucin 3

References

  1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadekndorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  PubMed  CAS  Google Scholar 

  2. Robert C, Thomas L, Bondarenko I, O’Day S, Webe J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.

    Article  PubMed  CAS  Google Scholar 

  3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

    Article  PubMed  CAS  Google Scholar 

  4. Yuan ZR, Wang R, Solomon J, Luo X, Sun H, Zhang L, Shi Y. Identification and characterization of survival-related gene, a novel cell survival gene controlling apoptosis and tumourigenesis. Cancer Res. 2005;65:10716–24.

    Article  PubMed  CAS  Google Scholar 

  5. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng TDS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16:2861–71.

    Article  PubMed  CAS  Google Scholar 

  6. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.

    Article  PubMed  CAS  Google Scholar 

  7. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumour vaccine. J Clin Oncol. 2007;25:2546–53.

    Article  PubMed  CAS  Google Scholar 

  8. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767–75.

    Article  PubMed  CAS  Google Scholar 

  9. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumour regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005–16.

    Article  PubMed  Google Scholar 

  10. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. Intratumoural immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009;15:390–9.

    Article  PubMed  CAS  Google Scholar 

  11. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. CTLA4 blockade induces frequent tumour infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011;17:4101–9.

    Article  PubMed  CAS  Google Scholar 

  12. Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS. Biomarkers on melanoma patient T Cells associated with ipilimumab treatment. J Transl Med. 2012;10:146.

    Article  PubMed  CAS  Google Scholar 

  13. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med. 1992;175:139–46.

    Article  PubMed  CAS  Google Scholar 

  14. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumour microenvironment. Curr Opin Immunol. 2011;23:286–92.

    Article  PubMed  CAS  Google Scholar 

  15. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69:3077–85.

    Article  PubMed  CAS  Google Scholar 

  16. Tang D, Billiar TA, Lotze MT. A Janus tale of two active HMGB1 redox states. Mol Med. 2012;12:00314.

    Google Scholar 

  17. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther. 2008;7:3642–53.

    Article  PubMed  CAS  Google Scholar 

  18. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, Bongarzone I, Rodolfo M. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia. 2011;13:1132–42.

    PubMed  CAS  Google Scholar 

  19. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF. Tumour-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30:2678–83.

    Article  PubMed  Google Scholar 

  20. Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med. 1995;181:811–6.

    Article  PubMed  CAS  Google Scholar 

  21. Delfortrie S, Pinte S, Mattot V, Samson C, Villain G, Caetano B, Lauridant-Philippin G, Baranzelli MC, Bonneterre J, Trottein F, Faveeuw C, Soncin F. Egfl7 promotes tumour escape from immunity by repressing endothelial cell activation. Cancer Res. 2011;71:7176–86.

    Article  PubMed  CAS  Google Scholar 

  22. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O’Brien-Jenkins A, Gimotty PA, Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumours and disables immune therapy. Nat Med. 2008;14:28–36.

    Article  PubMed  CAS  Google Scholar 

  23. Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res. 2009;15:4521–8.

    Article  PubMed  CAS  Google Scholar 

  24. Mangahas CR, dela Cruz GV, Friedman-Jimenez G, Jamal S. Endothelin-1 induces CXCL1 and CXCL8 secretion in human melanoma cells. J Invest Dermatol. 2005;125:307–11.

    PubMed  CAS  Google Scholar 

  25. Spinella F, Caprara V, Di Castro V, Rosano L, Cianfrocca R, Natali PG, Bagnato A. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med. 2012;11:1–11.

    Google Scholar 

  26. Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res. 2009;22:175–86.

    Article  PubMed  CAS  Google Scholar 

  27. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P. Redirecting migration of T cells to chemokine secreted from tumours by genetic modification with CXCR2. Hum Gene Ther. 2002;13:1971–80.

    Article  PubMed  CAS  Google Scholar 

  28. Chew V, Toh HC, Abastado JP. Immune microenvironment in tumour progression: characteristics and challenges for therapy. J Oncol. 2012;608406:8.

    Google Scholar 

  29. Fulton AM. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep. 2009;11:125–31.

    Article  PubMed  CAS  Google Scholar 

  30. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. NF-κB hyperactivation in tumour tissues allows tumour-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012;72:3735–43.

    Article  PubMed  CAS  Google Scholar 

  31. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumour microenvironment. Cancer Res. 2012;72:876–86.

    Article  PubMed  CAS  Google Scholar 

  32. Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH, Oude EMG, Molema G, Fuks F, van Engeland M, Griffioen AW. Epigenetic regulation of tumour endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006;66:10770–7.

    Article  PubMed  CAS  Google Scholar 

  33. Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer. 2010;9:69–80.

    Article  PubMed  Google Scholar 

  34. Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, Luis E, Tien J, Firestein R, Polakis P. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clin Cancer Res. 2011;17:965–75.

    Article  PubMed  CAS  Google Scholar 

  35. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012;18:2326–35.

    Article  PubMed  CAS  Google Scholar 

  36. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70:5213–9.

    Article  PubMed  CAS  Google Scholar 

  37. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma R, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18:1386–94.

    Article  PubMed  CAS  Google Scholar 

  38. Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU. Selective BRAF inhibition decreases tumour-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology. 2012;1:609–17.

    Article  PubMed  Google Scholar 

  39. Khalili JS, Liu S, Rodriguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizee G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012;18:5329–40.

    Article  PubMed  CAS  Google Scholar 

  40. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505–9.

    Article  PubMed  CAS  Google Scholar 

  41. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–4.

    Article  PubMed  CAS  Google Scholar 

  42. Gallagher PG, Bao Y, Prorock A, Zigrino P, Nischt R, Politi V, Mauch C, Dragulev B, Fox JW. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumour interactions in metastasis. Cancer Res. 2005;65:4134–46.

    Article  PubMed  CAS  Google Scholar 

  43. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM. CD8(+) T cells specific for tumour antigens can be rendered dysfunctional by the tumour microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012;72:887–96.

    Article  PubMed  CAS  Google Scholar 

  44. Nagaraj S, Nelson A, Youn JI, Cheng P, Quiceno D, Gabrilovich DI. Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 2012;72:928–38.

    Article  PubMed  CAS  Google Scholar 

  45. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61:255–63.

    Article  PubMed  CAS  Google Scholar 

  46. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167:195–205.

    Article  PubMed  CAS  Google Scholar 

  47. Richmond A, Nf-κB. Chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002;2:664–74.

    Article  PubMed  CAS  Google Scholar 

  48. Ueda Y, Richmond A. NF-κB activation in melanoma. Pigment Cell Res. 2006;19:112–24.

    Article  PubMed  CAS  Google Scholar 

  49. Liu J, Suresh KKG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY. Oncogenic BRAF regulates beta-Trcp expression and NF-κB activity in human melanoma cells. Oncogene. 2007;26:1954–8.

    Article  PubMed  CAS  Google Scholar 

  50. Becker TM, Rizos H, de la Pena A, Leclercq IA, Woodruff S, Kefford RF, Mann GJ. Impaired inhibition of NF-κB activity by melanoma-associated p16INK4a mutations. Biochem Biophys Res Commun. 2005;332:873–9.

    Article  PubMed  CAS  Google Scholar 

  51. Thu YM, Su Y, Yang J, Splittgerber R, Na S, Boyd A, Mosse C, Simons C, Richmond A. NF-κB inducing kinase (NIK) modulates melanoma tumourigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Oncogene. 2012;31:2580–92.

    Article  PubMed  CAS  Google Scholar 

  52. Yang J, Kantrow S, Sai J, Hawkins OE, Boothby M, Ayers GD, Young ED, Demicco EG, Lazar AJ, Lev D, Richmond A. Ikk4a/Arf inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Cancer Res. 2012;72:4682–95.

    Article  PubMed  CAS  Google Scholar 

  53. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol. 2007;20:416–26.

    Article  PubMed  CAS  Google Scholar 

  54. Hoejberg L, Bastholt L, Schmidt H. Interleukin-6 and melanoma. Melanoma Res. 2012;22:327–33.

    Article  PubMed  CAS  Google Scholar 

  55. Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA. NF-κB as potential target in the treatment of melanoma. J Transl Med. 2012;10:53–61.

    Article  PubMed  CAS  Google Scholar 

  56. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: involvement of nuclear factor κB and mitochondria pathways. Clin Cancer Res. 2006;12:950–60.

    Article  PubMed  CAS  Google Scholar 

  57. Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F. Tumour necrosis factors blocking agents: analogies and differences. Acta Biomed. 2012;83:72–80.

    PubMed  CAS  Google Scholar 

  58. Deal Watch. BMS acquires rights for IL-6 inhibitor. Nat Rev Drug Discov. 2010;9:10.

    Google Scholar 

  59. Vaddi K, Luchi M. JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy. Expert Opin Investig Drugs. 2012;21:961–73.

    Article  PubMed  CAS  Google Scholar 

  60. Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther. 2003;3:141–68.

    Article  PubMed  CAS  Google Scholar 

  61. Ostermeier E, Roll P, Tony HP. Janus kinase inhibitors. Z Rheumatol. 2012;71:473–8.

    Article  PubMed  CAS  Google Scholar 

  62. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee K, Tarakhovsky A. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119–23.

    Article  PubMed  CAS  Google Scholar 

  63. Seal J, Lamotte Y, Donche F, Bouillot A, Mirguet O, Gellibert F, Nicodeme E, Krysa G, Kirilovsky J, Beinke S, McCleary S, Rioja I, Bamborough P, Chung CW, Gordon L, Lewis T, Walker AL, Cutler L, Lugo D, Wilson DM, Witherington J, Lee K, Prinjha RK. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett. 2012;22:2968–72.

    Article  PubMed  CAS  Google Scholar 

  64. Martinez FI, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I. Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda. J Transl Med. 2012;10:108.

    Article  Google Scholar 

Download references

Conflicts of Interest

No potential conflicts of interest are disclosed.

Author information

Authors and Affiliations

  1. Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia

    Peter Hersey, Stuart Gallagher & Branka Mijatov

Authors
  1. Peter Hersey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Branka Mijatov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Hersey .

Editor information

Editors and Affiliations

  1. Molecular Genetics, University of California, Los Angeles Dept. Microbiology, Immunology &, Los Angeles, California, USA

    Benjamin Bonavida

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hersey, P., Gallagher, S., Mijatov, B. (2013). Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors. In: Bonavida, B. (eds) Resistance to Immunotherapeutic Antibodies in Cancer. Resistance to Targeted Anti-Cancer Therapeutics, vol 2. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7654-2_7

Download citation

Publish with us

Policies and ethics

Search

Navigation